Achieving lipid goals in Europe: How large is the treatment gap?

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 3, 2004, Pages 431-449

  Schwandt, Peter ^a   Brady Jr , Adrian J B ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cholesterol; Coronary heart disease; Dyslipidemia; Lipid lowering therapy; Statins; Undertreatment; Underuse

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ANGINA PECTORIS; ASIA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; EUROPE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MORBIDITY; MORTALITY; POPULATION DISTRIBUTION; POPULATION RESEARCH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; WORLD HEALTH ORGANIZATION;

ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; EUROPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; RISK FACTORS;

EID: 2542429438     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.3.431     Document Type: Review

References (79)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
2. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307 (1995).
3. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001-1009 (1996).
4. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Airforce/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998).
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357 (1998).
6. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630 (2002).
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
8. Sever PS, Dahlof B, Poulter NR et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003).
9. ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998-3007 (2002).
10. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. J. Cardiovasc. Prev. Rehabil. 10(Suppl. 1), S2-S78 (2003).
11. Schwandt P. The importance of reaching lipid targets: statins and the prevention of atherosclerosis. Int. J. Clin. Pract. 57, 396-404 (2003).
12. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
13. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. N. Engl. J. Med. 317, 1237-1245 (1987).
14. Rubins HB, Robins SJ, Collins D et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341, 410-418 (1999).
15. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102, 21-27 (2000).
16. Parhofer KG, Geiss HC, Schwandt P. Efficacy of different low-density lipoprotein apheresis methods. Ther. Apher. 321, 382-385 (2000).
17. Schwandt P. Lipid apheresis: the only therapeutic option for a very small group of cardiovascular patients with high low-density cholesterol or lipoprotein (a) blood concentrations. Ther. Apher. Dial. 7, 283-284 (2003).
18. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur. Heart J. 22, 554-572 (2001).
19. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur. Heart J. 18, 1569-1582 (1997).
20. Steg PG, Goldberg RJ, Gore JM et al. for the GRACE Investigators. Baseline characteristics, management practices and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am. J. Cardiol. 90, 358-363 (2002).
21. Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thornson A. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 88, 25-29 (2002).
22. Department of Health. National Service Framework for Coronary Heart Disease. Department of Health, London, UK (2000).
23. Underwood P, Beck P. Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues. Qual. Saf. Health Care 11, 230-232 (2002).
24. Cozma IS, Ogunko A, Rees A. Secondary prevention of hypercholesterolaemia: results of an audit conducted in South Wales. Heart 84, E3 (2000).
25. Charalambous C, Cleanthous S, Siddique I, Keenan D, Malik R, Heagerty AM. Secondary prevention in patients awaiting CABG in the North West of England. Br. J. Cardiol. 9, 488-489 (2002).
26. Missouris CG, Kalaitzidis RG, Parchure N, Ziakka S, Ward D, Singer DR. Coronary heart disease in the statin and aspirin era: are results of clinical trials being put into practice? Eur. J. Intern. Med. 12, 490-495 (2001).
27. Dutta D, Ogunnaike B. Lipid lowering after myocardial infarction in hospital practice. Br. J. Clin. Gov. 7, 154-157 (2002).
28. Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24431 patients with coronary heart disease: survey in primary care. Br. Med. J. 322, 1463 (2001).
29. Brady AJB, Pittard JB, Grace JF, Robinson PJ. Four year sequential review (1999-2002) of statin treatment in 11,996 patients with established CHD: the Healthwise audit. Heart, A58 (2003)(Abstract 196).
30. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid-lowering drugs: evidence from a national cross sectional survey. Br. Med. J. 321, 1322-1325 (2000).
31. Reid FDA, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 88, 15-19 (2002).
32. Wright DJ, Grayson AD, Jackson M, Dainty C. The reality of treating dyslipidaemia in patients with coronary heart disease: a primary care survey. Int. J. Clin. Pract. 57, 488-491 (2003).
33. Carroll K, Majeed A, Firth C, Gray J. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J. Public Health Med. 25, 29-35 (2003).
34. De Lusignan S, Dzregah B, Hague N, Chan T. Cholesterol management in patients with IHD: an audit-based appraisal of progress towards clinical targets in primary care. Br. J. Cardiol. 10, 223-228 (2003).
35. Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. Clin. Pharmacol. Ther. 67, 438-441 (2000).
36. Muls E, De Backer G, De Bacquer D, Brohet M, Heller F. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Clin. Drug Invest. 19, 219-229 (2000).
37. Devroey D, de Swaef N, Coigniez P, Vandevoorde J, Kartounian J, Betz W. Results from a cardiovascular prevention campaign in persons aged 45-64 years. Int. J. Clin. Pract. 57, 430-434 (2003).
38. Marques-Vidal P, Ruidavets J-B, Cambou J-P, Ferrières J. Trends in the prevalence, awareness and treatment of hypercholesterolemia in Southwestern France. CVD Prevention 3, 18-25 (2002).
39. Danchin N, Grenier O, Ferrieres J, Cantet C, Cambou JP. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 88, 159-162 (2002).
40. Ruof J, Klein G, Marz W, Wollschlager H, Neiss A, Wehling M. Lipid-lowering medication for secondary prevention of coronary heart disease in a German population: the gap between treatment guidelines and real life treatment patterns. Prev. Med. 35, 48-53 (2002).
41. Laubach E, Otto C, Schwandt P. Toward better therapy of hypercholesterolemia. Arch. Intern. Med. 160, 2685-2686 (2000).
42. Harder S, Mohr O, Klepzig H. Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory out-patient clinic. Int. J. Clin. Pharmacol. Ther. 39, 534-538 (2001).
43. Bergmann A, Schulze J, Hüber D, Weizel A, Julius U, Kreuzer J. Lipid-lowering therapy and cholesterol levels following acute myocardial infarction: a German study of 5361 patients. Eur. J. Epidemiol. 18, 407-411 (2003).
44. Houterman S, Verschuren WM, Oomen CM, Boersma-Cobbaert CM, Kromhout D. Trends in total and high density lipoprotein cholesterol and their determinants in The Netherlands between 1993 and 1997. Int. J. Epidemiol. 30, 1063-1070 (2001).
45. Mantel-Teeuwisse AK, Klungel OH, Verschuren WMM, Porsius AJ, de Boer A. Time trends in hpid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br. J. Clin. Pharmacol. 53, 379-385 (2002).
46. Mantel-Teeuwisse AK, Verschuren WMM, Klungel OH et al. Undertreatment of hypercholesterolaemia: a population-based study. Br. J. Clin. Pharmacol. 55, 387-397 (2003).
47. Spiess A, Roos M, Frisullo R et al. Cardiovascular drug utilization and its determinants in unselected medical patients with ischemic heart disease. Eur. J. Intern. Med. 13, 57-64 (2002).
48. Muntwyler J, Noseda G, Darioli R, Gruner C, Gutzwiller F, Follath F. National survey on prescription of cardiovascular drugs among out-patients with coronary artery disease in Switzerland. Swiss. Med. Wkl. 133, 88-92 (2003).
49. NHS Executive Standing Medical Advisory Committee statement on use of statins. Department of Health, London, UK (1997).
50. Rallidis LS, Zolindaki MG, Chatziioakimidis VK, Velissaridou AH, Konstantellou ES, Papasteriadis EG. High prevalence and suboptimal treatment of risk factors in Greek coronary patients. Acta Cardiol. 56, 7-15 (2001).
51. Shilo L, Feldman J, Gendlman V, Shenkman L, Berner YN. Is the treatment of hyperlipidemia as secondary prevention adequate in different age groups in Israel? Isr. Med. Assoc. J. 5, 479-481 (2003).
52. Gaspardone A, Proietti I, Altamura L et al. The use over time of statins in coronary patients in an Italian tertiary referral center. Ital. Heart J. 2, 848-853 (2001).
53. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269, 3015-3023 (1993).
54. Fornengo P, Bruno G, De Salvia A, Arcari R, Pisu E, Pagano G. Low adherence of general practitioners to National Cholesterol Education program guidelines for the management of hyperlipidaemia. Diab. Nutr. Metab. 13, 263-268 (2000).
55. Cesari M, Maiolino G, Colona S et al. Under treatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study. J. Cardiovasc. Pharmacol. 42, 484-490 (2003).
56. Velasco JA, Cosin J, Lopez Sendon JL et al. Secondary prevention of myocardial infarction in Spain. The PREVESE study. Rev. Esp. Cardiol. 50, 406-415 (1997).
57. Velasco JA, Cosin J, Lopez-Sendon JL, De Teresa E, De Oya M, Sellers G. New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study. Rev. Esp. Cardiol, 55, 801-809 (2002).
58. Bjerrum L, Larsen J, Kragstrup J. Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing. Scand. J. Prim. Health Care 19, 158-162 (2001).
59. Larsen J, Viccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br. J. Clin. Pharmacol. 49, 463-471 (2000).
60. Kastarinen M, Tuomilehto J, Vartianen E et al. Trends in lipid levels and hypercholesterolemia in hypertensive and normotensive Finnish adults from 1982 to 1997. J. Intern. Med. 247, 53-62 (2000).
61. Strandberg TE, Vanhanen H. Long standing heart disease should be better screened. Br. Med. J. 321, 1083-1084 (2000).
62. Strandberg TE, Pitkala K, Kulp S, Tilvis RS. Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older. Eur. J. Clin. Pharmacol. 57, 513-516 (2001).
63. Vikman S, Airaksinen KE, Peuhkurinen K et al. Gap between guidelines and management of patients with acute coronary syndrome without persistent ST elevation. Finnish prospective follow-up survey. Scand Cardiovasc. J. 37, 187-192 (2003).
64. Sigurdsson EL, Jonsson JS, Thorgeirsson G. Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland. Scand. J. Prim. Health Gare 20, 10-15 (2002).
65. Svilaas A, Thoresen M, Kristoffersen JE, Hjartaaker J, Westheim A. How well are patients with atherosclerotic disease treated? Scand. J. Prim. Health Care 18, 232-236 (2000).
66. Svilaas A, Risberg K, Thoresen M, Ose L. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am. J. Cardiol. 86, 1250-1253 (2000).
67. Cederholm J, Nilsson PM, Anderberg C-P, Fröberg L, Petersson U. Blood pressure and other cardiovascular risk factors among treated hypertensives in Swedish primary healthcare. Scand. J. Prim. Health Care 20, 224-229 (2002).
68. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285, 430-436 (2001).
69. Kawecka-Jaszcz K, Jankowski P, Pajak A. Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian Program for secondary prevention of ischaemic heart disease. Int. J. Cardiol. 91, 15-23 (2003).
70. Skibinska. E, Musial WJ, Prokop J, Bachorzewska-Gajewska H, Kowalska I, Kinalska I. How secondary prevention is implemented in clinical practice in male patients with a 2-year history of coronary heart disease. Kardiol. Pol. 56, 281 (2002).
71. Sonmez K, Akcay A, Akcakoyun M et al. Distribution of risk factors and prophylactic drug usage in Turkish patients with angiographically established coronary artery disease. J. Cardiovasc. Risk 9, 199-205 (2002).
72. Baltali M, Kiziltan HT, Korkmaz ME et al. Prevalence of modifiable cardiovascular risk factors remain high after coronary bypass graft surgery. J. Cardiovasc. Risk 9, 207-214 (2002).
73. Walley T, Folino-Gallo P, Schwabe U, van Ganse E on behalf of the EuroMEdStat group. Variations and increase in use of statins across Europe: data from administrative databases. Br. Med. J. 328, 285-386 (2004).
74. Andrews T, Ballantyne CM, Hsia J, Kramer J. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am. J. Med. 111, 185-191 (2001).
75. Kritharides L. Reducing low-density lipoprotein cholesterol - treating to target and meeting new European goals. Eur. Heart J. 6(Suppl. A), A1-A7 (2004).
76. Berenson GS, Pickoff AS. Preventive cardiology and its potential influence on the early natural history of adult heart diseases: the Bogalusa Heart Study and the Heart Smart Program. Am. J. Med. Sci. 310(Suppl. 1), S133-S138 (1995).
77. Schwandt P, Geiss HC, Ritter MM et al. The Prevention Education Program (PEP). A prospective study on the efficacy of family-oriented life style modification in the reduction of cardiovascular risk and disease. Design and baseline data. J. Clin. Epidemiol. 52, 791-800 (1999).
78. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol. 86, 5-18 (2002).
79. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. 326, 1419-1423 (2003).